Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $23.72 | N/A | +28.26% |
management commentary, guidance changes, and full analysis available with Pro.
| +28.26% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings results, highlighting their commitment to innovation. They emphasized the importance of continuing to meet patient needs in the coming quarters.
We are pleased with our performance this quarter.
Our focus remains on innovation and meeting patient needs.
Regeneron Pharmaceuticals reported strong earnings with an EPS beat, which contributed to a slight increase in stock price. The positive surprise in EPS indicates strong operational performance, although no revenue figures were disclosed. The stock reaction suggests that investors are encouraged by the earnings results, even without specific guidance for the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALPHABET INC Class A
Feb 1, 2022